Vyvanse is a successor to Adderall XR for attention deficit hyperactivity disorder. CRH Plc (CRH ID) fell 15 cents, or 0.8 percent, to 25.93 euros. ...
Vyvanse is a successor to Adderall XR for attention deficit hyperactivity disorder. Thomas Cook Group Plc (TCG LN), Europe's second-biggest tour operator, ...
"This not only entails converting patients from Adderall XR but also the more significant patient population currently using alternative therapies. ...
He cited concerns over Vyvanse, the group's replacement for its blockbuster treatment for attention deficit hyperactivity disorder (ADHD), Adderall XR, ...
... because of worries about its Vyvanse hyperactivity drug, which is designed to replace the block-buster Adderall XR, whose patent expires next year. ...
... because of worries about its Vyvanse hyperactivity drug, which is designed to replace the block-buster Adderall XR, whose patent expires next year. ...
About 18 percent of Adderall XR patients are now using Vyvanse, Cacciatore said. Generic versions of Adderall can be sold in April 2009, while Vyvanse is ...
... Clinical Research at Shire Pharmaceuticals where he was responsible for clinical drug development of key programs that included Adderall XR, ...
... Clinical Research at Shire Pharmaceuticals where he was responsible for clinical drug development of key programs that included Adderall XR, ...
... Clinical Research at Shire Pharmaceuticals where he was responsible for clinical drug development of key programs that included Adderall XR, ...